BA
SNOA icon

Bard Associates’s Sonoma Pharmaceuticals SNOA Stock Holding History

Bard Associates’s Portfolio SNOA Stock Details SNOA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-2,325
Closed -$341K – 178
2021
Q2 		$341K Buy
2,325
+10
+0.4% +$1.57K 0.11% 138
2021
Q1 		$344K Hold
2,315
– – 0.12% 130
2020
Q4 		$336K Hold
2,315
– – 0.13% 124
2020
Q3 		$388K Sell
2,315
-15
-0.6% -$2.31K 0.21% 107
2020
Q2 		$332K Sell
2,330
-271
-10% -$32.6K 0.18% 113
2020
Q1 		$255K Sell
2,601
-411
-14% -$41.4K 0.19% 110
2019
Q4 		$262K Buy
3,012
+1,783
+145% +$178K 0.13% 131
2019
Q3 		$142K Sell
1,229
-124
-9% -$16K 0.07% 147
2019
Q2 		$214K Sell
1,353
-56
-4% -$8.6K 0.11% 136
2019
Q1 		$239K Sell
1,409
-18
-1% -$2.72K 0.12% 138
2018
Q4 		$183K Sell
1,427
-444
-24% -$88.6K 0.11% 141
2018
Q3 		$492K Sell
1,871
-5
-0.3% -$1.82K 0.23% 112
2018
Q2 		$837K Buy
1,876
+54
+3% +$35.2K 0.39% 96
2018
Q1 		$1.21M Sell
1,822
-35
-2% -$28.8K 0.6% 70
2017
Q4 		$1.83M Buy
1,857
+1,176
+173% +$1.01M 0.88% 37
2017
Q3 		$639K Sell
681
-2
-0.3% -$2.17K 0.3% 103
2017
Q2 		$814K Hold
683
– – 0.37% 98
2017
Q1 		$881K Sell
683
-15
-2% -$17.4K 0.41% 90
2016
Q4 		$633K Buy
698
+57
+9% +$47.3K 0.29% 99
2016
Q3 		$501K Sell
641
-5
-0.8% -$3.75K 0.24% 108
2016
Q2 		$466K Buy
646
+3
+0.5% +$2.58K 0.25% 107
2016
Q1 		$553K Sell
643
-3
-0.5% -$2.79K 0.32% 98
2015
Q4 		$668K Buy
+646
New +$688K 0.39% 87
2014
Q3 		– Sell
-21
Closed -$59K – 173
2014
Q2 		$59K Sell
21
-198
-90% -$586K 0.02% 182
2014
Q1 		$742K Sell
219
-8
-4% -$27.2K 0.31% 109
2013
Q4 		$708K Sell
227
-26
-10% -$69.1K 0.29% 111
2013
Q3 		$623K Buy
253
+178
+237% +$434K 0.28% 119
2013
Q2 		$174K Buy
+75
New +$268K 0.08% 166

Other funds holding SNOA

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
Squarepoint
Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
RE
RBC Europe London, United Kingdom $2.08B AUM 12.2% 1-Year Est. Return

Bard Associates's SNOA Position: Q3 2021 in Review

Bard Associates sold out of Sonoma Pharmaceuticals (SNOA) in Q3 2021, closing a stake of 2,325 shares — an estimated $341K sold.

Bard Associates first reported a position in SNOA in Q2 2013 and held it in 28 quarters. The position peaked at $1.83M in Q4 2017. 20 funds tracked by Wall St. Rank hold SNOA as of Q3 2021.

  • Bard Associates reported no remaining Sonoma Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Bard Associates sold 2,325 Sonoma Pharmaceuticals shares in Q3 2021, an estimated $341K.
  • Bard Associates first reported a position in Sonoma Pharmaceuticals in Q2 2013 and held it in 28 quarters.
  • Bard Associates's Sonoma Pharmaceuticals position peaked at $1.83M in Q4 2017.
  • 20 funds tracked by Wall St. Rank held Sonoma Pharmaceuticals as of Q3 2021.

Based on Bard Associates's 13F filing for Q3 2021, filed 12 Nov 2021.